Adaptive Biotechnologies Corporation
Latest round
- Series F
Last raised
- May 2015
Total raised
- $307M
Investors
- 7
About Adaptive Biotechnologies Corporation
Founded in 2009 and headquartered in Seattle, US, Adaptive Biotechnologies Corporation specializes in harnessing the adaptive immune system for diagnostics and therapeutics. The company was co-founded by Chad Robins and Harlan Robins.00 mn.Adaptive Biotechnologies specializes in innovative diagnostics and therapeutics harnessing the adaptive immune system, primarily through its flagship product, clonoSEQ. This assay employs next-generation sequencing (NGS) technology to assess minimal residual disease (MRD) in patients undergoing treatment for lymphoid malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma. By identifying and quantifying disease-associated immune receptor DNA, clonoSEQ offers a highly sensitive and specific measurement that significantly enhances the understanding of treatment efficacy and disease progression. The company's products are utilized by leading drug developers, clinical researchers, and healthcare providers, with a strong emphasis on improving patient outcomes in the oncology space.Adaptive Biotechnologies generates revenue primarily through its clonoSEQ MRD testing services, utilized in both clinical and biopharmaceutical settings.996 mn. Revenue is derived from direct transactions with healthcare providers and biopharma companies who utilize the testing services either on a per-test basis or as part of larger strategic partnerships. The company benefits from extensive insurance coverage for its diagnostic services, enabling widespread access for patients and healthcare professionals. The company is focused on developing additional assays and expanding the applications of clonoSEQ in oncology treatments. Furthermore, the company is exploring opportunities to enter emerging markets in Asia and Europe by 2025, where there is significant potential for growth in the biotechnology sector.
Who invested in Adaptive Biotechnologies Corporation
7 investors across 4 rounds
See all investors in Adaptive Biotechnologies Corporation
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Adaptive Biotechnologies Corporation
Who invested in Adaptive Biotechnologies Corporation?
Adaptive Biotechnologies Corporation has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adaptive Biotechnologies Corporation raised?
Adaptive Biotechnologies Corporation has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Adaptive Biotechnologies Corporation last raise money?
Adaptive Biotechnologies Corporation's most recent round on record is a Series F, in May 2015.
What does Adaptive Biotechnologies Corporation do?
Founded in 2009 and headquartered in Seattle, US, Adaptive Biotechnologies Corporation specializes in harnessing the adaptive immune system for diagnostics and therapeutics.
Where is Adaptive Biotechnologies Corporation headquartered?
Adaptive Biotechnologies Corporation is headquartered in Seattle, US.
Which VCs invest in companies like Adaptive Biotechnologies Corporation?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Adaptive Biotechnologies Corporation's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series F
Raising like Adaptive Biotechnologies Corporation? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.